UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the Month of January
Commission File Number 000-50994
BioProgress PLC
(Translation of registrant’s name into English)
15-17 Cambridge Science Park
Milton Road, Cambridge CB4 0FQ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):N/A
.
For Immediate Release 25 January 2007
BioProgress plc
Arab Health 2007
London, UK, 25 January 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and
healthcare announces that it will be showing its technologies and products at Arab Health, Dubai on 29 January - 01 February.
Arab Health is attended by over 33,000 visitors with 2,200 exhibiting companies. With many of the global and regional pharmaceutical
companies attending, Arab Health 2007 offers BioProgress a central forum targeting a global audience. We plan to extend our strategic
relationships, and target additional distributors for our current portfolio of over 40 pharmaceutical and healthcare products, and
five commercialised enabling systems.
For more details on Arab Health 2007, visit www.arabhealthonline.com.
Steve Martin, Chief Development Officer said:
"Arab Health is an important forum to show our products and technologies to a wide global audience. This is the first time we have
shown at Arab Health and represents a significant step forward for the company where we are showcasing over 40 products, and a range
of unique enabling drug delivery systems."
For further information:
BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich / Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer
and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in
application within 24 patent families and has product development agreements and strategic alliances with several global companies.
As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch
mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™
polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further
information please go to www.bioprogress.com
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this
announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The
forward-looking statements in this release include statements addressing future financial and operating results and the timing and
benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual
results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no
obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of
new information, future events or otherwise. This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of
securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to
inform themselves about and to observe such restrictions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.